We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+39.82%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11.4B
AUM Growth
+$3.47B
Cap. Flow
+$1.27B
Cap. Flow %
11.12%
Top 10 Hldgs %
37.58%
Holding
169
New
25
Increased
27
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$384M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$292M
3
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$154M
4
PFE icon
Pfizer
PFE
+$133M
5
UNH icon
UnitedHealth
UNH
+$131M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$259M
2
XLRN
Acceleron Pharma
XLRN
+$67.6M
3
ASND icon
Ascendis Pharma A/S
ASND
+$65.8M
4
EXEL icon
Exelixis
EXEL
+$58.8M
5
BIIB icon
Biogen
BIIB
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98.2%
2 Financials 0.52%
3 Technology 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
51
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$64.2M 0.56%
1,125,700
– –
MGTX icon
52
MeiraGTx Holdings
MGTX
$1.08B
$62.1M 0.54%
4,102,925
+389,105
+10% +$5.5M
ELVN icon
53
Enliven Therapeutics
ELVN
$3.78B
$60M 0.52%
679,976
– –
ADVM
54
DELISTED
Adverum Biotechnologies
ADVM
$59.6M 0.52%
550,114
+91,680
+20% +$11.3M
EHTH icon
55
eHealth
EHTH
$41.9M
$59.6M 0.52%
844,046
+205,488
+32% +$15.6M
CHNG
56
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$57.7M 0.5%
3,093,700
– –
SYK icon
57
Stryker
SYK
$135B
$57.6M 0.5%
235,000
– –
ASND icon
58
Ascendis Pharma A/S
ASND
$16.5B
$56.1M 0.49%
336,500
-398,000
-54% -$65.8M
ARCT icon
59
Arcturus Therapeutics
ARCT
$165M
$55.5M 0.49%
1,280,086
+661,500
+107% +$44.8M
ACHC icon
60
Acadia Healthcare
ACHC
$2.52B
$52M 0.46%
1,035,160
-79,306
-7% -$3.16M
TMO icon
61
Thermo Fisher Scientific
TMO
$214B
$51.4M 0.45%
110,300
– –
DMRA
62
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.74B
$51.2M 0.45%
+163,637
New +$60.9M
MREO
63
Mereo BioPharma
MREO
$48.9M
– –
0
– –
TELA icon
64
TELA Bio
TELA
$30.3M
$45.5M 0.4%
3,027,542
– –
TRIL
65
DELISTED
Trillium Therapeutics Inc.
TRIL
$43.5M 0.38%
2,960,200
+1,707,600
+136% +$24.6M
SIBN icon
66
SI-BONE Inc
SIBN
$818M
$40.9M 0.36%
1,368,500
– –
ATNX
67
DELISTED
Athenex, Inc. Common Stock
ATNX
$40.9M 0.36%
184,703
-14,195
-7% -$3.49M
VRNA
68
DELISTED
Verona Pharma
VRNA
$39.9M 0.35%
5,694,841
– –
APLT
69
DELISTED
Applied Therapeutics
APLT
$39M 0.34%
1,771,831
+225,144
+15% +$4.69M
CRNX icon
70
Crinetics Pharmaceuticals
CRNX
$8.88B
$38.9M 0.34%
2,753,567
– –
ALPN
71
DELISTED
Alpine Immune Sciences Inc
ALPN
$38.7M 0.34%
3,070,955
-600,000
-16% -$5.89M
XENE icon
72
Xenon Pharmaceuticals
XENE
$6.1B
$38.4M 0.34%
2,497,917
– –
FUSN
73
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$37.9M 0.33%
3,224,770
– –
KALA icon
74
KALA BIO
KALA
$12.5M
$37.1M 0.32%
2,188
– –
CRIS icon
75
Curis
CRIS
$9.71M
$35.8M 0.31%
10,916
+7,812
+252% +$9.38M
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q4 2020 Portfolio in Review

As of Q4 2020, OrbiMed held 169 positions worth $11.4B, up 44% from $7.96B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $1.27B of net new capital in Q4 2020, opening 25 new positions and adding to 27 existing holdings. Its largest new stake was AbCellera Biologics: 8,400,768 shares worth $338M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $259M trimmed.

  • OrbiMed's largest Q4 2020 buy was AbCellera Biologics: 8,400,768 shares worth $338M.
  • OrbiMed added most to Xtant Medical Holdings in Q4 2020, an estimated $81.8M increase.
  • OrbiMed's biggest Q4 2020 reduction was Alexion Pharmaceuticals, cutting an estimated $259M.
  • OrbiMed fully exited Acceleron Pharma in Q4 2020, selling an estimated $67.6M.
  • OrbiMed's ten largest holdings make up 38% of its $11.4B portfolio in Q4 2020.
  • OrbiMed opened 25 new positions and closed 20 in Q4 2020.
  • OrbiMed's portfolio value rose 44% quarter-over-quarter to $11.4B.

Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.